Search Results | Blood | American Society of Hematology

1-20 of 3541

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis

Akash Parekh, Frank G Keller, Kathleen M McCarten, Sandy Kessel, Steve Cho, Qinglin Pei, Yue Wu, Sharon M Castellino, Louis S. Constine, Cindy L Schwartz, David Hodgson, Kara M. Kelly, Bradford S. Hoppe

Blood blood.2022016098.

DOI: https://doi.org/10.1182/blood.2022016098

Published: 2022

Includes: Supplemental data

Journal Articles

Introduction to a review series on immunotherapies for nonmalignant hematologic diseases

Catherine M. Bollard

Blood (2022) 139 (25): 3561.

DOI: https://doi.org/10.1182/blood.2022016022

Published: 2022

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

DOI: https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data

Peter Bruun-Rasmussen, Per Kragh Andersen, Karina Banasik, Søren Brunak, Pär Ingemar Johansson

Blood (2022) 139 (25): 3647–3654.

DOI: https://doi.org/10.1182/blood.2022015892

Published: 2022

Includes: Supplemental data

Journal Articles

Introduction to a review series on pediatric hematology

Thomas L. Ortel, Irene Roberts

Blood blood.2022017225.

DOI: https://doi.org/10.1182/blood.2022017225

Published: 2022

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood blood.2021014901.

DOI: https://doi.org/10.1182/blood.2021014901

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Blood (2022) 139 (24): 3546–3557.

DOI: https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

A study of ruxolitinib response–based stratified treatment for pediatric hemophagocytic lymphohistiocytosis

Qing Zhang, Yun-Ze Zhao, Hong-Hao Ma, Dong Wang, Lei Cui, Wei-Jing Li, Ang Wei, Chan-Juan Wang, Tian-You Wang, Zhi-Gang Li, Rui Zhang

Blood (2022) 139 (24): 3493–3504.

DOI: https://doi.org/10.1182/blood.2021014860

Published: 2022

Includes: Supplemental data

Journal Articles

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

David T. Yeung, Naranie Shanmuganathan, Timothy P. Hughes

Blood (2022) 139 (24): 3474–3479.

DOI: https://doi.org/10.1182/blood.2021014689

Published: 2022

Journal Articles

Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma, Marc Michel, Ilene C Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M.I. Vos, Michael Storek, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardecki, Frank Shafer, Michelle Lee, Catherine M. Broome

Blood blood.2021014955.

DOI: https://doi.org/10.1182/blood.2021014955

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Blood (2022) 139 (23): 3376–3386.

DOI: https://doi.org/10.1182/blood.2021013733

Published: 2022

Includes: Supplemental data

Journal Articles

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Blood (2022) 139 (23): 3366–3375.

DOI: https://doi.org/10.1182/blood.2021011583

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes Following Treatment for Adenosine Deaminase Deficient Severe Combined Immunodeficiency: A Report from the PIDTC

Geoffrey D.E. Cuvelier, Brent R Logan, Susan Prockop, Rebecca H. Buckley, Caroline Y. Kuo, Linda M Griffith, Xuerong Liu, Alison Yip, Michael Hershfield, Paul Ayoub, Theodore B Moore, Morna Dorsey, Richard J O'Reilly, Neena Kapoor, Sung-Yun Pai, Malika Kapadia, Christen L Ebens, Lisa R Forbes Satter, Lauri Burroughs, Aleksandra Petrovic, Deepak Chellapandian, Jennifer Heimall, David Shyr, Ahmad Rayes, Jeffrey J Bednarski, Sharat Chandra, Shanmuganathan Chandrakasan, Alfred P Gilio, Lisa M. Madden, Troy C Quigg, Emi H Caywood, Blachy J Dávila Saldaña, Kenneth DeSantes, Hesham Eissa, Frederick D Goldman, Jacob Rozmus, Ami Shah, Mark T Vander Lugt, Monica S Thakar, Roberta E Parrott, Caridad A Martinez, Jennifer W Leiding, Troy R. Torgerson, Michael A Pulsipher, Luigi D Notarangelo, Morton J Cowan, Christopher C Dvorak, Elie Haddad, Jennifer M. Puck, Donald B Kohn

Blood blood.2022016196.

DOI: https://doi.org/10.1182/blood.2022016196

Published: 2022

Includes: Supplemental data

Journal Articles

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo controlled, randomized clinical trial

Terry B Gernsheimer, Siobhan P Brown, Darrell J Triulzi, Nigel S Key, Nahed El Kassar, Heather Herren, Jacqueline N Poston, Michael Boyiadzis, Brandi N. Reeves, Subodh Selukar, Monica B Pagano, Scott S Emerson, Susanne May

Blood blood.2022016308.

DOI: https://doi.org/10.1182/blood.2022016308

Published: 2022

Includes: Supplemental data

Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Blood (2022) 139 (22): 3278–3289.

DOI: https://doi.org/10.1182/blood.2021014488

Published: 2022

Includes: Supplemental data

Journal Articles

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Blood (2022) 139 (21): 3148–3158.

DOI: https://doi.org/10.1182/blood.2021014162

Published: 2022

Includes: Supplemental data

Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood blood.2021015014.

DOI: https://doi.org/10.1182/blood.2021015014

Published: 2022

Includes: Supplemental data

Journal Articles

CD19/22 CAR T-cells in Children and Young Adults with B-ALL: Phase I Results and Development of a Novel Bicistronic CAR

Blood blood.2022015795.

DOI: https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma

AnnaLynn M. Williams, Sedigheh Mirzaei Salehabadi, Mengqi Xing, Nicholas S. Phillips, Matthew J. Ehrhardt, Rebecca Howell, Yutaka Yasui, Kevin C. Oeffinger, Todd Gibson, Eric J. Chow, Wendy Leisenring, Deokumar Srivastava, Melissa M. Hudson, Leslie L. Robison, Gregory T. Armstrong, Kevin R. Krull

Blood (2022) 139 (20): 3073–3086.

DOI: https://doi.org/10.1182/blood.2021013167

Published: 2022

Includes: Supplemental data

Journal Articles

Patients with CLL have lower risk of death from COVID-19 in the omicron era

Carsten Utoft Niemann, Caspar da Cunha-Bang, Marie Helleberg, Sisse R Ostrowski, Christian Brieghel

Blood blood.2022016147.

DOI: https://doi.org/10.1182/blood.2022016147

Published: 2022

Includes: Supplemental data

2 3 4 5

NARROW

Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis

Introduction to a review series on immunotherapies for nonmalignant hematologic diseases

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data

Introduction to a review series on pediatric hematology

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

A study of ruxolitinib response–based stratified treatment for pediatric hemophagocytic lymphohistiocytosis

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Outcomes Following Treatment for Adenosine Deaminase Deficient Severe Combined Immunodeficiency: A Report from the PIDTC

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo controlled, randomized clinical trial

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

CD19/22 CAR T-cells in Children and Young Adults with B-ALL: Phase I Results and Development of a Novel Bicistronic CAR

Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma

Patients with CLL have lower risk of death from COVID-19 in the omicron era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only